Clinical Research & Development Through Patient Partnership

In the SUISSE MPC-2 study, a phase II clinical trial exploring a novel cell-based therapy for women with stress urinary incontinence, the teams from University of Zurich and MUVON Therapeutics, faced a unique set of challenges. The condition itself is often surrounded by stigma, making open discussion difficult for many women. In addition, the study’s design included strict eligibility criteria and was conducted at a single site, which further limited access for potential participants. Given the novelty of the investigated treatment, clear, honest, and empathetic communication was essential to build trust and encourage participation.

The objective was to break through barriers of awareness and trust and reach potential eligible patients who might benefit from this therapy. Recognizing that patients are not just study subjects but true partners in research, admedicum stepped in with its recruitment approach, a modular framework designed to support patients at every stage of their journey. This approach was built to ensure that individuals felt informed, understood, and empowered.

admedicum contributed to a seamless and efficient recruitment process by combining patient engagement expertise with strategic, operational, and regulatory know-how. Through these combined efforts, the clinical study turned recruitment into an efficient and collaborative process. By addressing the voices and concerns of women with stress urinary incontinence, patient-focused engagement broke down barriers, built trust, and encouraged participation.